

**MISSISSIPPI DIVISION OF MEDICAID**  
**Pharmacy & Therapeutics Committee**  
**Virtual Meeting**  
**August 10, 2021**  
**9:00am to 5:00pm**

**AGENDA**

- I. Call to Order
- II. Welcome & Introductions
- III. Administrative Matters
- IV. Approval of October 27, 2020 Meeting Minutes
- V. PDL Compliance/Generic Percent Report Updates
- VI. Drug Class Announcements
- VII. First Round of Extractions
- VIII. Public Comments
- IX. Second Round of Extractions
- X. Motion for All Non-Extracted New Drugs to be Approved as Proposed
  - a. Analgesics/Anesthetics – Licart (diclofenac epolamine)
  - b. Analgesic, Opioid- Short Acting - Qdolo (tramadol)
  - c. Anticonvulsants- Elepsia XR (levetiracetam)
  - d. Antineoplastics - Selected Systemic Enzyme Inhibitors
    1. Fotivda (tivozanib)
    2. Gavreto (pralsetinib)
    3. Inqovi (cedazuridine/decitabine)
    4. Onureg (azacitidine)
    5. Orgovyx (relugolix)
    6. Tepmetko (tepotinib)
    7. Ukoniq (umbralisib)
  - e. Antiparkinson’s Agents – Ongentys (opicapone)
  - f. Factory Deficiency Products – Sevenfact (coagulation factor VIIa)
  - g. Glucocorticoids (Inhaled)
    1. Airduo Digihaler (fluticasone propionate/salmeterol xinafoate)
    2. Armonair Digihaler (fluticasone propionate)
  - h. Hypoglycemics, Insulins and Related Agents – Semglee (insulin glargine, recombinant)
  - i. Ophthalmics, Dry Eye Agents – Eysuvis (loteprednol etabonate)
  - j. Select Contraceptive Products
    1. Nextstellis (drospirenone/estetrol)
    2. Phexxi (lactic acid/citric acid/potassium bitartrate)
    3. Twirla (ethinyl estradiol/levonorgestrel)
  - k. Steroids (Topical), Very High Potency – Impeklo (clobetasol propionate) lotion
  - l. Stimulants and Related Agents, Narcolepsy – Xywav (calcium oxybate/magnesium oxybate/potassium oxybate/sodium oxybate)

- XI. Extracted New Drug/New Generic Reviews
  - a. Antiretrovirals – Cabenuva (cabotegravir/rilpivirine)
  - b. Bladder Relaxant Preparations – Gemtesa (vibegron)
  - c. Cystic Fibrosis Agents - Bronchitol (mannitol)
  - d. Hereditary Angioedema – Orladeyo (berotralstat)
  - e. Hypoglycemia Treatment, Glucagon-- Zegalogue (dasiglucagon)
  - f. Lipotropics, Other- Non-Statins-- Evkeeza (evinacumab-dgnb)
  - g. Miscellaneous- Verquvo (vericiguat)
  - h. Multiple Sclerosis Agents
    - 1. Kesimpta (ofatumumab)
    - 2. Ponvory (ponesimod)
  - i. Muscular Dystrophy Agents- Amondys 45 (casimersen)
  - j. Stimulants & Other Related Agents - Qelbree (viloxazine)
- XII. Division of Medicaid Update
- XIII. Next Meeting Date-Tuesday, October 19, 2021
- XIV. Adjournment